Drug intelligence / Profile preview

ZL-85

Development stage: Unknown
Lead developer: Zenitar
Modality: Small Molecules

Overview

ZL-85 is a small molecule drug candidate developed by Chengdu Zenitar Biomedical Technology Co., Ltd. It functions as a Poly (ADP-Ribose) polymerase 1 (PARP1) inhibitor. PARP inhibitors are a class of drugs that exploit deficiencies in DNA repair pathways, such as those found in BRCA1/2-mutated cancers, leading to synthetic lethality in cancer cells. ZL-85 is currently in the IND Application stage of development, with its primary indication being solid tumors.

Targets

PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on ZL-85.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZL-85.

Explore the full profile